We are live on ! Find out more
IIA

IPG Investment Advisors Portfolio holdings

AUM $582M
1-Year Est. Return 33.22%
This Fund
S&P 500
This Quarter Est. Return
-9.25%
1 Year Est. Return
+33.22%
3 Year Est. Return
+78.57%
5 Year Est. Return
+87.09%
10 Year Est. Return
+385.27%
AUM
$523M
AUM Growth
-$29.5M
Cap. Flow
+$47M
Cap. Flow %
8.99%
Top 10 Hldgs %
51.86%
Holding
233
New
27
Increased
65
Reduced
47
Closed
62

Top Buys

Rank Stock Value
1
AAPL icon
Apple
AAPL
+$27.8M
2
GT icon
Goodyear
GT
+$26.1M
3
CX icon
Cemex
CX
+$12.3M
4
MGA icon
Magna International
MGA
+$11.9M
5
WDC icon
Western Digital
WDC
+$9.79M

Top Sells

Rank Stock Value
1
TEF
Telefonica
TEF
+$21.4M
2
HMC icon
Honda
HMC
+$7.31M
3
HPQ icon
HP
HPQ
+$6.9M
4
HPE icon
Hewlett Packard
HPE
+$6.13M
5
MBB icon
iShares MBS ETF
MBB
+$4.77M

Sector Composition

Rank Sector Weight
1 Technology 27.36%
2 Consumer Discretionary 22.32%
3 Communication Services 9.35%
4 Industrials 8.16%
5 Financials 5.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GME icon
151
GameStop
GME
$8.6B
$208K 0.04%
+5,000
New +$148K
FDX icon
152
FedEx
FDX
$75.4B
$207K 0.04%
895
HOOD icon
153
Robinhood
HOOD
$83.9B
$183K 0.04%
+13,580
New +$182K
OTLY
154
Oatly Group
OTLY
$438M
$165K 0.03%
1,650
-2,450
-60% -$323K
VTRS icon
155
Viatris
VTRS
$18.9B
$113K 0.02%
10,369
CELU icon
156
Celularity
CELU
$20.3M
$109K 0.02%
+1,254
New +$75.1K
BBVA icon
157
Banco Bilbao Vizcaya Argentaria
BBVA
$156B
$82K 0.02%
14,405
-1,425
-9% -$8.72K
SCPH
158
DELISTED
scPharmaceuticals
SCPH
$81K 0.02%
14,300
ML
159
DELISTED
MoneyLion Inc.
ML
$65K 0.01%
867
+400
+86% +$31.2K
VRNA
160
DELISTED
Verona Pharma
VRNA
$59K 0.01%
11,900
IFRX icon
161
InflaRx
IFRX
$271M
$47K 0.01%
25,900
PHAS
162
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$38K 0.01%
28,900
CTMX icon
163
CytomX Therapeutics
CTMX
$754M
$33K 0.01%
12,500
ONCT
164
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$33K 0.01%
1,185
HIPO icon
165
Hippo Holdings
HIPO
$861M
$28K 0.01%
560
+120
+27% +$6.2K
SLDB icon
166
Solid Biosciences
SLDB
$900M
$21K ﹤0.01%
1,193
KALA icon
167
KALA BIO
KALA
$14.5M
$20K ﹤0.01%
6
ZKIN icon
168
ZK International Group
ZKIN
$61.9M
$17K ﹤0.01%
1,863
TMQ
169
Trilogy Metals
TMQ
$656M
$15K ﹤0.01%
14,850
ADVM
170
DELISTED
Adverum Biotechnologies
ADVM
$13K ﹤0.01%
1,000
ORTX
171
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$10K ﹤0.01%
1,410
ADBE icon
172
Adobe
ADBE
$105B
-2,601
Closed -$1.48M
AR icon
173
Antero Resources
AR
$10.7B
-19,000
Closed -$333K
ARKG icon
174
ARK Genomic Revolution ETF
ARKG
$1.73B
-4,356
Closed -$267K
ARW icon
175
Arrow Electronics
ARW
$10.4B
-31,850
Closed -$4.28M

Similar funds

IPG Investment Advisors's Q1 2022 Portfolio in Review

As of Q1 2022, IPG Investment Advisors held 233 positions worth $523M, down 5.3% from $553M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

IPG Investment Advisors deployed $47M of net new capital in Q1 2022, opening 27 new positions and adding to 65 existing holdings. Its largest new stake was BorgWarner: 218,487 shares worth $7.48M.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Communication Services.

On the sell side, the largest reduction was iShares 0-1 Year Treasury Bond ETF, an estimated $4.55M trimmed.

  • IPG Investment Advisors's largest Q1 2022 buy was BorgWarner: 218,487 shares worth $7.48M.
  • IPG Investment Advisors added most to Apple in Q1 2022, an estimated $27.8M increase.
  • IPG Investment Advisors's biggest Q1 2022 reduction was iShares 0-1 Year Treasury Bond ETF, cutting an estimated $4.55M.
  • IPG Investment Advisors fully exited Telefonica in Q1 2022, selling an estimated $21.4M.
  • IPG Investment Advisors's ten largest holdings make up 52% of its $523M portfolio in Q1 2022.
  • IPG Investment Advisors opened 27 new positions and closed 62 in Q1 2022.
  • IPG Investment Advisors's portfolio value fell 5.3% quarter-over-quarter to $523M.

Based on IPG Investment Advisors's 13F filing for Q1 2022, filed 13 May 2022.